Research Topics
Species | Miquel VilaSummaryAffiliation: Columbia University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Targeting programmed cell death in neurodegenerative diseasesMiquel Vila
Department of Neurology, Columbia University, 650 West 168th Street, BB-307, New York, New York 10032, USA
Nat Rev Neurosci 4:365-75. 2003- The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's diseaseSerge Przedborski
Neuroscience Research Laboratories of the Movement Disorder Division, Department of Neurology, Columbia University, New York, New York 10032, USA
Ann N Y Acad Sci 991:189-98. 2003..How to target these factors to devise effective neuroprotective therapies for PD is also discussed... - The rotenone model of Parkinson's diseaseCeline Perier
Trends Neurosci 26:345-6. 2003 
D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson diseaseKim Tieu
Department of Neurology, Columbia University, New York, New York, USA
J Clin Invest 112:892-901. 2003..Because of the safety record of ketone bodies in the treatment of epilepsy and their ability to penetrate the blood-brain barrier, DbetaHB may be a novel neuroprotective therapy for PD...- Interfering with programmed cell death in neurodegenerative diseases: insights from experimental animal modelsMiquel Vila
Drug Discov Today 9:513-4. 2004 - L-3-hydroxyacyl-CoA dehydrogenase II protects in a model of Parkinson's diseaseKim Tieu
Department of Neurology, Columbia University, New York, NY 10032, USA
Ann Neurol 56:51-60. 2004..This study demonstrates that HADH II/ABAD modulates MPTP neurotoxicity and suggests that HADH II/ABAD mimetics may provide protective benefit in the treatment of PD... - MPTP as a mitochondrial neurotoxic model of Parkinson's diseaseSerge Przedborski
Department of Neurology, Columbia University, New York, New York 10032, USA
J Bioenerg Biomembr 36:375-9. 2004..How mitochondria are affected by MPTP and how their defect contributes to the demise of dopaminergic neurons in this model of PD are discussed in this review... - Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in miceDong-Kug Choi
Department of Neurology, Columbia University, New York, New York 10032, USA
J Neurosci 25:6594-600. 2005..This study demonstrates that MPO participates in the MPTP neurotoxic process and suggests that inhibitors of MPO may provide a protective benefit in PD... - Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damageCeline Perier
Department of Neurology, Columbia University, New York, NY 10032, USA
Proc Natl Acad Sci U S A 102:19126-31. 2005..This molecular scenario may have far-reaching implications for the development of effective neuroprotective therapies for these incurable illnesses... - Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson diseaseD C Wu
Department of Neurology, Columbia University, New York, New York 10032, USA
J Neurosci 22:1763-71. 2002..This study demonstrates that microglial-related inflammatory events play a significant role in the MPTP neurotoxic process and suggests that minocycline may be a valuable neuroprotective agent for the treatment of PD... - NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's diseaseDu-Chu Wu
Department of Neurology, Columbia University, New York, NY 10032, USA
Proc Natl Acad Sci U S A 100:6145-50. 2003..This study supports a critical role for NADPH-oxidase in the pathogenesis of PD and suggests that targeting this enzyme or enhancing extracellular antioxidants may provide novel therapies for PD... - Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's diseaseCeline Perier
Research Institute University Hospital Vall d Hebron, 08035 Barcelona, Spain
Proc Natl Acad Sci U S A 104:8161-6. 2007..These results provide further insight into the pathogenesis of PD neurodegeneration and identify molecular targets of potential therapeutic significance for this disabling neurological illness... - Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTPWilliam Dauer
Department of Neurology, Columbia University, New York, NY 10027, USA
Proc Natl Acad Sci U S A 99:14524-9. 2002.... - Free radical and nitric oxide toxicity in Parkinson's diseaseSerge Przedborski
Departments of Neurology and Pathology, Columbia University, New York, New York, USA
Adv Neurol 91:83-94. 2003 - Neurodegeneration: what is it and where are we?Serge Przedborski
Department of Neurology, Columbia University, New York, New York 10032, USA
J Clin Invest 111:3-10. 2003 - Pathogenic role of glial cells in Parkinson's diseasePeter Teismann
Neuroscience Research, Movement Disorder Division, Department of Neurology, Columbia University, New York, New York 10032, USA
Mov Disord 18:121-9. 2003..We discuss the potential protective and deleterious effects of glial cells in the SNpc of PD and examine how those factors may contribute to the pathogenesis of this disease... - Glial cell response: A pathogenic factor in Parkinson's diseaseDu Chu Wu
Neuroscience Research, Movement Disorder Division, Department of Neurology, Columbia University, New York, New York, USA
J Neurovirol 8:551-8. 2002..In this review, the authors discuss the potential protective and deleterious effects of glial cells in the SNpc of PD and examine how these factors may contribute to the pathogenesis of this disease... - JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's diseaseStephane Hunot
Section of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA
Proc Natl Acad Sci U S A 101:665-70. 2004..Our data revealed that JNK2- and JNK3-induced COX-2 may be a principle pathway responsible for neurodegeneration in PD... - Genetic clues to the pathogenesis of Parkinson's diseaseMiquel Vila
Department of Neurology, Center for Neurobiology and Behavior, Columbia University, New York, New York 10032, USA
Nat Med 10:S58-62. 2004..These breakthroughs have not provided a direct explanation for the disease process. Nevertheless, they have helped transform Parkinson's disease research by providing tangible clues to the neurobiology of the disorder... - Instrumental activation of bid by caspase-1 in a transgenic mouse model of ALSChristelle Guegan
Department of Neurology, Columbia University, New York, New York 10032, USA
Mol Cell Neurosci 20:553-62. 2002.... - Increased expression and redistribution of the antiapoptotic molecule Bcl-xL in Parkinson's diseaseAndreas Hartmann
INSERM U 289, Hopital de la Salpetriere, 75013 Paris, France
Neurobiol Dis 10:28-32. 2002..We also show that, ultrastructurally, this effect may be mediated by a redistribution of Bcl-x(L) from the cytosol to the outer mitochondrial membrane... - Metabolic changes in the basal ganglia of patients with Huntington's disease: an in situ hybridization study of cytochrome oxidase subunit I mRNAIsabelle Gourfinkel-An
INSERM U289, , Paris, France
J Neurochem 80:466-76. 2002.... - Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegenerationPeter Teismann
Neuroscience Research Laboratories of the Movement Disorder Division, Department of Neurology, Columbia University, New York, NY 10032, USA
Proc Natl Acad Sci U S A 100:5473-8. 2003..Because of the safety record of the COX-2 inhibitors, and their ability to penetrate the blood-brain barrier, these drugs may be therapies for PD...
Research Grants
- Mechanisms of Bax-mediated cell death in the MPTP modelMiquel Vila; Fiscal Year: 2004..Collectively, the proposed studies should shed light on the molecular mechanisms of neurodegeneration in PD and help to identify new molecular targets for therapeutic intervention. ..